Endo Rapid Acting Insulin Analog Vs Regular Human Insulin Basal Bolus High Risk

Rapid-Acting Insulin Analog vs Regular Human Insulin for Basal-Bolus Therapy at High Hypoglycemia Risk

STEP 1 — Gather Information

Confirm patient is on basal-bolus insulin therapy; assess for high hypoglycemia risk factors: history of severe hypoglycemia requiring assistance, impaired awareness of hypoglycemia (IAH), or renal/hepatic dysfunction. Document prandial insulin needs and current insulin regimen.

STEP 2 — Rule In / Rule Out

If any high-risk factor is present, proceed to stratify; if no high-risk factors are identified, consider regular human insulin for prandial dosing after shared decision-making about hypoglycemia risk tolerance.

STEP 3 — Classify or Stratify

Stratify by predominant risk factor: prior severe hypoglycemia requiring assistance (highest urgency) vs IAH or renal/hepatic dysfunction (moderate urgency); this guides intensity of hypoglycemia education and monitoring planning.

STEP 4 — Decide

Prescribe a rapid-acting insulin analog (aspart, lispro, glulisine, or faster aspart) for prandial boluses; avoid regular human insulin in basal-bolus therapy for patients stratified as high hypoglycemia risk.

Clinical Guardrails / Mimics / Pitfalls

Do not use rapid-acting analogs without addressing basal insulin timing and dose; do not overlook cost/access barriers that may lead to medication nonadherence; do not ignore need for hypoglycemia education when IAH is present; do not assume analog eliminates hypoglycemia risk without lifestyle and basal adjustments; do not use in pregnancy without obstetric endocrinology consultation.

Concrete Clinical Example

A 16-year-old with type 1 diabetes on basal-bolus therapy experiences two episodes of severe hypoglycemia requiring glucagon in the past month and reports frequent hypoglycemia unawareness. After confirming high risk (prior severe hypoglycemia + IAH), the clinician prescribes insulin lispro for meals instead of regular human insulin, arranges CGM initiation, and reviews carbohydrate counting.

Source: Management of Individuals With Diabetes at High Risk for Hypoglycemia: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2023, https://doi.org/10.1210/clinem/dgac596